



Lung fibrosis from gene defects

Treatment with Hydroxychloroquine

International contact:

Prof. Dr. Matthias Griese
Coordinator

Matthias.griese@med.uni-muenchen.de

National contact

see below

www.childeu.net



Objective

Investigating the efficacy and safety of hydroxychloroquine (HCQ) in genetic interstitial lung disease (ILD)

Inclusion Criteria

- Patients of all ages, with a genetically diagnosed ILD related to surfactant dysfunction disorders
- Chronic diffuse parenchymal lung disease (DPLD, chILD)

Duration

3 month treatment, 3 month follow up

The study

Hydroxychloroquin or Placebo, once daily
Oxygenation, quality of life, lung function with walking distance, blood, vital signs, ECG, cardiac echo

Participating sites

- Hospital Universitari Vall d'Hebron, Barcelona, **Spain**,
Contact: Dr. Moreno-Galdo'
- Hospital Clinico Universitario Valencia, **Spain**,
Contact: Dr. Escribano
- Hospital La Paz, ;Madrid, **Spain**,
Contact: Dr. Barrio
- Hospital 12 de Octubre, Madrid **Spain**,
Contact: Dr. Luna
- Medical University Warsawa, **Poland**,
Contact: Dr. Lange
- Jagiellonian University Med. College, Krakow, **Poland**, **Contact: Dr. Lis**
- Bambino Gesù Pediatric Hospital, Rome, **Italy**,
Contact: Dr. Cutrera, Dr. Ullmann
- G. Gaslini Institute, Genova, **Italy**,
Contact: Dr. Sacco
- Hacettepe University Ankara, **Turkey**,
Contact: Dr. Kiper
- Gazi University Ankara, **Turkey**,
Contact: Dr. Aslan, Dr. Sismanlar
- Medical University Vienna, **Austria**,
Contact: Dr. Szeffalusi
- Medical University Graz, **Austria**,
Contact: Dr. Eber
- Hospital de Santa Maria, Lisboa, **Portugal**,
Contact: Dr. Bandeira
- Hauner Childrens' Hospital, Munich, **Germany**,
Contact: Dr. Griese